We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Liver cancer

News List

Nexavar receives final appraisal for primary liver cancer europeanpharmaceuticalreview
August 11, 2017
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma…
First new promising treatment in a decade for primary liver cancer patients europeanpharmaceuticalreview
May 02, 2017
Results of the SARAH trial demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular carcinoma (HCC).
Q BioMed in Cancer Development Pact contractpharma
February 08, 2017
Q BioMed has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer.
FDA grants priority review for Bayer’s liver cancer treatment europeanpharmaceuticalreview
January 05, 2017
The US Food and Drug Administration (FDA) has granted priority review status for the supplemental new drug application for Stivarga (regorafenib, Bayer), as a second line systemic treatment of patients with hepatocellular carcinoma (HCC) in the US.

Previous page 1 2 3 4 5 Next page